Cargando…

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab

BACKGROUND: We recently reported a 56% objective response rate in patients with advanced Merkel cell carcinoma (MCC) receiving pembrolizumab. However, a biomarker predicting clinical response was not identified. METHODS: Pretreatment FFPE tumor specimens (n = 26) were stained for CD8, PD-L1, and PD-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giraldo, Nicolas A., Nguyen, Peter, Engle, Elizabeth L., Kaunitz, Genevieve J., Cottrell, Tricia R., Berry, Sneha, Green, Benjamin, Soni, Abha, Cuda, Jonathan D., Stein, Julie E., Sunshine, Joel C., Succaria, Farah, Xu, Haiying, Ogurtsova, Aleksandra, Danilova, Ludmila, Church, Candice D., Miller, Natalie J., Fling, Steve, Lundgren, Lisa, Ramchurren, Nirasha, Yearley, Jennifer H., Lipson, Evan J., Cheever, Mac, Anders, Robert A., Nghiem, Paul T., Topalian, Suzanne L., Taube, Janis M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167897/ https://www.ncbi.nlm.nih.gov/pubmed/30285852 http://dx.doi.org/10.1186/s40425-018-0404-0

Ejemplares similares

Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy
por: Miller, Natalie J., et al.
Publicado: (2018)

Measurement of PD-L1 in melanoma: a quantitative antibody comparison
por: Sunshine, Joel C, et al.
Publicado: (2015)

PD-L1 Expression in Inflammatory Myofibroblastic Tumors
por: Cottrell, Tricia R., et al.
Publicado: (2018)

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
por: Nghiem, Paul, et al.
Publicado: (2021)

PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy
por: Simon, Sylvain, et al.
Publicado: (2020)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy
por: Greene, Evan, et al.
Publicado: (2021)

Immune cell subsets in interface cutaneous immune‐related adverse events associated with anti‐PD‐1 therapy resemble acute graft versus host disease more than lichen planus
por: Almodovar Cruz, Guillermo E., et al.
Publicado: (2022)

Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
por: Phillips, Darci, et al.
Publicado: (2021)

Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma
por: Deutsch, Julie Stein, et al.
Publicado: (2023)

Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome
por: Su, Tianying, et al.
Publicado: (2022)

Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series
por: LoPiccolo, Jaclyn, et al.
Publicado: (2019)

PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors
por: Wang, Jaeyun Jane, et al.
Publicado: (2019)

Are there Multiple Cells of Origin of Merkel Cell Carcinoma?
por: Sunshine, J. C., et al.
Publicado: (2018)

Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
por: Spassova, Ivelina, et al.
Publicado: (2022)

Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma
por: Tachiki, Lisa May Ling, et al.
Publicado: (2023)

PD-L1 expression in medulloblastoma: an evaluation by subgroup
por: Martin, Allison M., et al.
Publicado: (2018)

Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma
por: Hanna, Glenn J., et al.
Publicado: (2020)

Response to Anti-PD-1 Therapy in Metastatic Merkel Cell Carcinoma Metastatic to the Heart and Pancreas
por: Mantripragada, Kalyan, et al.
Publicado: (2015)

Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec
por: Singh, Neha, et al.
Publicado: (2023)

The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers
por: Barrett, Michael T., et al.
Publicado: (2018)

Detection of Merkel cell virus and correlation with histologic presence of Merkel cell carcinoma in sentinel lymph nodes
por: Loyo, M, et al.
Publicado: (2012)

Association of Merkel Cell Polyomavirus–Specific Antibodies With Merkel Cell Carcinoma
por: Carter, Joseph J., et al.
Publicado: (2009)

Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma
por: Church, Candice, et al.
Publicado: (2022)

Mechanisms regulating PD-L1 expression on tumor and immune cells
por: Chen, Shuming, et al.
Publicado: (2019)

Immunotherapy for Merkel cell carcinoma: a turning point in patient care
por: Chan, Isaac S., et al.
Publicado: (2018)

Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies
por: Lipson, Evan J.
Publicado: (2013)

Does a new polyomavirus contribute to Merkel cell carcinoma?
por: Garneski, Kelly M, et al.
Publicado: (2008)

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
por: Heinzerling, Lucie, et al.
Publicado: (2016)

Addressing Peritoneal Dialysis: In Vitro PD Models, In Vivo Rodent PD Model, Clinical Biobanks, and Underutilization of PD
por: Beelen, Robert H. J., et al.
Publicado: (2016)

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
por: Pachynski, Russell K, et al.
Publicado: (2021)

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
por: Smith, Kellie N., et al.
Publicado: (2019)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

The PD-1:PD-L1 axis in Inflammatory Arthritis
por: Canavan, Mary, et al.
Publicado: (2021)

A Dichotomy in Cross-Coupling Site Selectivity in a Dihalogenated Heteroarene: Influence of Mononuclear Pd, Pd Clusters, and Pd Nanoparticles—the Case for Exploiting Pd Catalyst Speciation
por: Scott, Neil W. J., et al.
Publicado: (2021)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures
por: Cheung, Laurene S, et al.
Publicado: (2021)

P29. T-cell responses to oncogenic Merkel cell polyomavirus proteins distinguish Merkel cell carcinoma patients from healthy donors
por: Lyngaa, L, et al.
Publicado: (2014)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Biomaterial-Mediated Genetic Reprogramming of Merkel Cell Carcinoma and Melanoma Leads to Targeted Cancer Cell Killing In Vitro and In Vivo
por: Luly, Kathryn M, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6sp7dgd4lp5muqc8iguitjiq7b